Ipamorelin

Ipamorelin is a synthetic peptide that mimics ghrelin to stimulate growth hormone release, valued in research for its selectivity. In Australia it is a prescription-only (Schedule 4) compounded peptide, not registered on the ARTG.

What it is

Ipamorelin is a synthetic pentapeptide classed as a growth hormone secretagogue (GHS) — a compound that prompts the pituitary gland to release growth hormone (GH). It belongs to the same family as older compounds like GHRP-2 and GHRP-6, but was developed to be more selective. It is frequently discussed alongside CJC-1295; the two are different molecules acting on different receptors, paired because their mechanisms are seen as complementary.

How it works

Ipamorelin mimics ghrelin, the body's "hunger hormone", by binding to the growth hormone secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activating this receptor triggers a pulse of GH release, which raises IGF-1. Its defining feature in research is selectivity: earlier secretagogues also raised cortisol, prolactin and ACTH, whereas ipamorelin released GH without significantly raising cortisol or ACTH in the original studies — a "cleaner" GH stimulus. Because it works through the ghrelin receptor rather than the GHRH receptor, ipamorelin and CJC-1295 act on two separate switches for GH release.

What the evidence says

Ipamorelin was first described by Raun and colleagues (European Journal of Endocrinology, 1998) as the first selective GH secretagogue. In animal and cell models it released GH with potency comparable to GHRP-6 but without the unwanted hormonal side effects. Human data are limited; it was investigated for gastrointestinal motility but not adopted as an approved therapy. The popular uses promoted online (fat loss, muscle building, anti-ageing, recovery) are not supported by robust, long-term human trials. Much of the evidence is pre-clinical or anecdotal.

Legal & regulatory status in Australia

Ipamorelin is a Schedule 4 (prescription-only) substance and is not registered on the ARTG, so it has not been assessed and approved by the TGA. It cannot be bought over the counter. Where supplied, it is dispensed by a compounding pharmacy against a doctor's prescription. Regulators have increased scrutiny of unapproved compounded GH-related peptides. Ipamorelin is also banned in sport under the WADA code (class S2).

Risks & considerations

Long-term human safety data are limited, so the risk profile is not fully established. Reported and theoretical concerns include headache, flushing, fluid retention, tiredness and effects on appetite and blood-sugar regulation. Because it acts on the ghrelin pathway, appetite effects are plausible. Products obtained outside the regulated supply chain add risks of impurity, mislabelling and incorrect dosing.

What to ask a doctor

• Is there a legitimate clinical indication for this in my case, and what proven alternatives exist?
• What does the human evidence actually show for my specific goal?
• What are the known side effects and the gaps in long-term safety data?
• If prescribed, what monitoring (IGF-1, blood glucose) and review schedule would apply?
• How is the quality and sterility of any compounded product assured?

FAQ

Q: Is ipamorelin legal to buy in Australia? A: It is a Schedule 4 prescription-only substance and is not on the ARTG, so it cannot be bought over the counter. Lawful access is only via a doctor's prescription, usually through a compounding pharmacy. Q: How is ipamorelin different from CJC-1295? A: Ipamorelin mimics ghrelin and acts on the GHSR-1a receptor, while CJC-1295 mimics GHRH and acts on the GHRH receptor. Q: Why is ipamorelin described as "selective"? A: In research models it raised GH without the cortisol, prolactin and ACTH increases seen with older secretagogues. Whether this translates to meaningful real-world benefit in humans is not established.